The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.

ABSTRACT:

SUBMITTER: Marson A 

PROVIDER: S-EPMC8047799 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature